Friday Satellite Symposia
Friday Satellite Symposia (FSS) are industry-supported, CME-certified symposia. These sessions are not part of the official ASH annual meeting program and are planned solely by the sponsoring company.
The 2023 FSS will be held on Friday, December 8. Each symposium will be presented once according to the program schedule and offers free registration. To register, click the “Registration” button below each title in the FSS program schedule. Check back as registration links will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each FSS session.
Please note, most, but not all sessions have a virtual component, and only some will be available on the annual meeting virtual platform. However, all sessions with a virtual component will be available (here) on the ASH website via the individual listings. Please review each listing carefully.
ASH appreciates its corporate and nonprofit partners for their participation in FSS. The Society values its partnerships and the supportive role that members of this community play in an effort to provide hematologists with quality educational programs. For more information, please review the 2023 FSS guidelines or contact Kelly Cade, Grants and Satellite Symposia Manager, Consultant, at [email protected].
1
Morning Symposia
7:00 a.m. - 10:00 a.m.
Pacific timeAdvances in the Treatment Paradigm of Myeloid Malignancies: From Biology to Clinical Practice
This program is supported by Cleveland Clinic and The Aplastic Anemia and MDS International Foundation
The Cleveland Clinic Center for Continuing Medical Education, Cleveland Clinic Taussig Cancer Institute, and the Aplastic Anemia and MDS International Foundation, Inc. (AAMDSIF) join together to present a live and enduring continuing medical education activity focusing on clonal hematopoiesis, low and high risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), aplastic anemia and paroxysmal nocturnal hemoglobinuria (AA & PNH) and cellular therapies for AML.
7:00 a.m. - 10:00 a.m. Pacific time
San Diego Convention Center
Room 6CFThis CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including AA, PNH, MDS, AML, MPN and related myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
Chair:
Sudipto Mukherjee , MD, PhD, MPH
Cleveland Clinic
Cleveland, OHSpeakers:
Uma M. Borate , MBBS, MS
The Ohio State University Comprehensive Cancer Center
Columbus, OHMarco Davila , MD, PhD
Roswell Park Comprehensive Cancer Center
Buffalo, NYAustin Kulasekararaj , MD, PhD, MPH
King's College Hospital
London, United KingdomEsther Natalie Oliva , MD
Grande Ospedale Metropolitano Bianchi Melacrino Morelli
Reggio Calabria, ItalyKristen Marie Pettit
C.S. Mott Children's Hospital
Ann Arbor, MIAbhay Singh , MD, MPH
Cleveland Clinic
Cleveland, OHKristin Bower , Cleveland Clinic
Registration for In-Person Program
Email: [email protected]Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This program is supported by Supported by educational grants from AstraZeneca, BeiGene, and Lilly. Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.
This NCCN-developed satellite symposium presents a great opportunity for healthcare professionals to interact with experts to be fully informed on the latest treatment advances in chronic lymphocytic leukemia (CLL). During the live event, the faculty will give an overview of recent clinical advances impacting today’s clinic along with emerging therapeutics in CLL. The symposium will also feature review of the latest updates to the NCCN Guidelines to help guide clinical application based on consensus recommendations and perspectives on emerging data. Data and guideline review will be complemented by panel discussions of various patient case scenarios with expert recommendations and supporting clinical data. NCCN Guidelines for Patients and PowerPoint slides outlining guideline recommendations will be made available to all in attendance. New developments on the near future horizon, including the utility of measurable residual disease and ongoing clinical trials of promising investigational approaches such as CAR T-cell therapy, will also be discussed. Text your questions directly to the panelists, and, throughout the program, the experts will take time to answer audience questions in order to provide their clinical approach, perspective, and interpretation of how the available clinical data should be applied to practice.
7:00 a.m. - 10:00 a.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 21-22Chair:
Brian T. Hill , MD, PhD
Cleveland Clinic
Cleveland, OHSpeakers:
Danielle M Brander , MD
Duke Cancer Center
Durham, NCDeborah M. Stephens , DO
University of Utah
Salt Lake City, UTIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramBEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Follicular, Mantle Cell and Hodgkin Lymphoma (Part 1 of a 4-part CME-accredited Symposia Series)
This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck and Seagen Inc.
This CME program, offered for in-person and virtual attendees, will focus on the management of follicular, mantle cell and Hodgkin lymphoma. Six investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.
7:00 a.m. - 10:00 a.m. Pacific time
Omni San Diego
Grand Ballroom, 4At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panelists will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty will deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.
Chair:
Neil Love , MD
Research To Practice
Key Biscayne, FLSpeakers:
Jeremy S. Abramson , MD
Massachusetts General Hospital Cancer Center
Boston, MAStephen M Ansell , MD, PhD
Mayo Clinic
Rochester, MNNancy L. Bartlett , MD
Washington University School of Medicine
Saint Louis, MOJonathon B. Cohen , MD,MS
Winship Cancer Institute, Emory University
Atlanta, GAJonathan W. Friedberg , MD, MMSc
University of Rochester
Rochester, NYBrad S. Kahl , MD
Washington University School of Medicine in St. Louis
Saint Louis, MOSylvia Eriksen , Research To Practice
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramExploring Unmarked Territory in MDS: Taking Command and Enhancing Care with Team-Based Diagnosis and Treatment for Lower- and Higher-Risk Disease
This program is supported by Bristol Myers Squibb, Geron Corporation, Karyopharm Therapeutics and Novartis Pharmaceuticals
This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.
7:00 a.m. - 10:00 a.m. Pacific time
San Diego Convention Center
Ballroom 20CDThis activity is supported through educational grants from Astex Pharmaceuticals, Inc., Bristol Myers Squibb, Geron, Karyopharm Therapeutics, and Novartis Pharmaceuticals Corporation.
The baseline assessment and subsequent management of myelodysplastic syndromes (MDS) is increasingly personalized to address the unique biology of this disorder and the well-recognized unmet medical needs of patients. PeerView’s unique Seminars & Tumor Board live event will explore this new therapeutic territory by pairing compelling case scenarios with collaborative real-world tumor board decision-making and, in doing so, provide expert guidance on the practice-changing evidence driving precision medicine in LR- and HR-MDS. Throughout, expert faculty will offer insights on 1) team-based methods for patient assessment, diagnosis, and prognostic assessment; 2) the challenges of characterizing and designing treatment plans for LR- and HR-MDS; 3) updated evidence supporting the use of innovative therapies for the 1L management of MDS anemia, ESA-refractory patients, and individuals presenting with high-risk mutations or cytogenetics (including TP53 mutations); and 4) practical strategies for effective delivery of care.
Speakers:
Rory M. Shallis , MD
Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center
Killingworth, CTAditi Shastri , MD
Albert Einstein College of Medicine
Bronx, NYLeigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramMedical Crossfire®:Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
This program is supported by Lilly, Merck and Co., Inc., Pharmacyclics
The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of BTK inhibitors creates practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the lymphoma care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into B-cell lymphoma treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.
7:00 a.m. - 10:00 a.m. Pacific time
San Diego Convention Center
Room 6BChair:
Ian W. Flinn , MD, PhD
Sarah Cannon Research Institute and Tennessee Oncology
Nashville, TNSpeakers:
Catherine C. Coombs , MD
University of California Irvine
Irvine, CAPaolo Strati , MD
The University of Texas MD Anderson Cancer Center
Houston, TXKelly Donald , Physicians Education Resources, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramMyelodysplastic Syndromes 2023: What’s New?
This program is supported by MDS Foundation, Inc.
The 2023 Symposium will focus on recent advances in the diagnosis, classification and management of patients with myelodysplastic syndromes (MDS) and will be presented via lecture, debate and patient discussions. The program combines recent data, application of new tools and evidence on current practice with information that might be applied in the future.
7:00 a.m. - 10:00 a.m. Pacific time
Marriott Marquis San Diego Marina
San Diego Ballroom ABChairs:
Moshe Mittelman , MD
Tel Aviv Sourasky Medical Center
Tel Aviv, IsraelRena Buckstein , MD, FRCPC
Sunnybrook Health Sciences Centre, University of Toronto
Toronto, ON, CanadaSpeakers:
Mario Cazzola , MD
University of Pavia
Pavia, ItalyMatteo Giovanni Della Porta , MD
Cancer Center IRCCS Humanitas Research Hospital
Milan, ItalyGuillermo Garcia-Manero , MD
University of Texas MD Anderson Cancer Center
Houston, TXAristoteles Giagounidis
Marienhospital Düsseldorf
Düsseldorf, GermanyChristopher James Gibson , MD
Dana Farber Cancer Institute
Boston, MAAziz Nazha , MD
Cleveland Clinic
Cleveland, OHUwe Platzbecker , MD
Leipzig University Hospital
Leipzig, GermanyMichael R. Savona , MD
Vanderbilt University Medical Center
Nashville, TNLea Harrison , MDS Foundation, Inc.
Registration for In-Person Program
Email: [email protected]Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
This program is supported by Regeneron Pharmaceuticals, Inc., Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.
This agenda format designed to bring together faculty together to have open conversations about the pressing issue of healthcare inequities seen in practice. This peer-to-peer exchange will foster and open and honest discussion on inequities and potential interventions that can be implemented to improve care for all patients with multiple myeloma.
7:00 a.m. - 10:00 a.m. Pacific time
San Diego Convention Center
Room 6AChair:
Irene M. Ghobrial , MD
Dana-Farber Cancer Institute
Boston, MASpeaker:
Craig Emmitt Cole , MD
Michigan State University
East Lansing, MIKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options
This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.
This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education, and developed with our educational partner HealthTree Foundation for Multiple Myeloma.
7:00 a.m. - 10:00 a.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 15-17This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.
A new therapeutic standard has been raised in multiple myeloma (MM). In the wake of successes with CD38 antibody platforms, it became clear that as patients were increasingly treated with a greater number of active agents, strategies with unique mechanisms of action were required for patients exposed to multiple lines of modern therapy. Enter the BCMA options, including antibody-drug conjugates, bispecific antibodies, and cellular therapy.
This symposium will take the story from there and offer expert-led, case-centered discussion on the major themes of treatment selection, sequencing across lines of therapy, and unique AE management that have emerged as new BCMA standards enter the clinic. Our experts will close each scientific segment by sharing resources from the HealthTree Foundation for Multiple Myeloma to support the real-world application of anti-BCMA platforms across the continuum of myeloma patient care. Join the experts in raising new standards of care for your patients with MM!
Chair:
Nikhil C. Munshi , MD
Jerome Lipper Multiple Myeloma Center, Harvard Medical School
Boston, MASpeakers:
Mohamad Mohty , MD,PhD
Saint-Antoine Hospital, Sorbonne University
Paris, FranceKrina K. Patel , MD, Msc
The University of Texas MD Anderson Cancer Center
Houston, TXLeigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual Program2
Early Afternoon Symposia
11:00 a.m. - 2:00 p.m.
Pacific timeA Master Class in Personalized Myelofibrosis Care: Applying New Evidence and Novel Therapeutic Strategies to Improve Outcomes
This program is supported by Educational grants from CTI Biopharma; Geron Corporation; GSK; and Karyopharm Therapeutics. Provided by Clinical Care Options, LLC.
During this symposium experts will review the latest data and provide practical insights on the diagnosis, risk stratification, and management of myelofibrosis (MF). As appropriate, each topic of the symposium will include a case review, didactic presentation, and interactive panel and audience engagement with opportunity for those in attendance to text questions and challenging case scenarios to the panelists. In this Master Class symposium participants can expect to interact with the experts as well as colleagues seated at your table to discuss data, guidelines, and disease factors that impact therapeutic decisions and then debate treatment recommendations for cases presented during the program. Discussion topics include: Partnering With Patients to Improve Outcomes and Quality of Life; Selecting Initial Treatment for Patients With Myelofibrosis; Recognizing Patterns of Suboptimal Response to Firstline MF Treatment; Beyond the First Line: Disease Progression or Intolerance to Initial Therapy; A Look to the Future: What’s on the Horizon in MF Treatment?
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
San Diego Ballroom ABSpeakers:
Jean-Jacques Kiladjian , MD,PhD
Hopital Saint-Louis
Paris, FranceAbdulraheem Yacoub , MD
The University of Kansas
Leawood, KSIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramAn MCL Quiz Game: Experts Review New and Emerging Therapies to Optimize Clinical Outcomes
This program is supported by An educational grant from AstraZeneca. Provided by Clinical Care Options, LLC.
The treatment of mantle cell lymphoma (MCL) is evolving. Join us for this innovative live satellite symposium that will feature a review and discussion of key clinical trial data with renowned clinical experts providing their perspectives focused specifically on BTK inhibitor-based therapy. In addition, enjoy a little friendly competition during the symposium as you will be challenged with a series of patient cases and polling questions presented as part of a Team Trivia style quiz game. Additionally, attendees will have ample ability to directly interact with the expert panel and contribute to the content of the program via submission of questions. Critical insights on the similarities and differences among multiple different BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. Discussion and case topics will include: 1) Recent updates to the treatment landscape in MCL; 2) Mechanisms, pharmacokinetics, pharmacodynamics, and efficacy of currently available BTK inhibitors; 3) The evolving role of BTK inhibitors in treatment-naïve MCL; 4) The management of relapsed/refractory disease considering resistance or intolerance to prior therapy; 5) Practical discussions with multiple expert perspectives on the implementation of new data and current clinical challenges.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 21-22Chair:
John P. Leonard
Weill Cornell Medicine
New York, NYSpeakers:
Ann LaCasce , MD
Dana Farber Cancer Institute
Boston, MAMatthew A Lunning , DO, FACP
Pathology and Microbiology University of Nebraska
Omaha, NEIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramBEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Diffuse Large B-Cell Lymphoma (Part 2 of a 4-part CME-accredited Symposia Series)
This program is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company and Regeneron Pharmaceuticals Inc
This CME-accredited program, offered for in-persom and virtual attendees, will focus on the management of patients with Diffuse Large B-Cell Lymphoma. Four investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 clinical investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns.
11:00 a.m. - 2:00 p.m. Pacific time
Omni San Diego
Grand Ballroom, 4At the live event, for each module, Dr Love will present results from the case-based survey and the faculty members on stage will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance (both in person and virtually) will have the opportunity to provide feedback on the same survey and present their own questions for discussion with the faculty.
Chair:
Neil Love , MD
Research To Practice
Key Biscayne, FLSpeakers:
Michael Dickinson , MBBS, D. Med Sci, FRACP, FRCPA
Peter MacCallum Cancer Centre and The Royal Melbourne Hospital
Melbourne, VIC, AustraliaGrzegorz S. Nowakowski , MD
Mayo Clinic
Rochester, MNGilles Salles , MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NYLaurie H. Sehn , MD, MPH
BC Cancer Centre for Lymphoid Cancer and The University of British Columbia
Vancouver, BC, CanadaJason Westin , MD
The University of Texas M D Anderson Cancer Center
Houston, TXSylvia Eriksen , Research To Practice
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramCAR T-Cell Therapies in Relapsed/Refractory Multiple Myeloma: Evaluating the Evidence for Optimal Integration
This program is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The evolution of CAR-T therapies – where do we stand now with this revolutionary treatment approach?
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 30 A-EJoin our faculty experts for this 1-hour accredited event about the current role of CAR T-cell therapies in management of patients with relapsed/refractory multiple myeloma (RRMM). Dr. Ajai Chari and Dr. Sikander Ailawadhi will discuss and debate practical challenges such as: Is prior treatment sequencing a significant factor in patient response to CAR T-cell therapy? Should all eligible patients with RRMM receive CAR T-cell therapy, or is fitness/frailty a concern? How can we prevent, identify, and manage adverse events? When is treatment discontinuation the best choice? What administration and cost issues need to be considered? And more...
Bring your hard-hitting questions - attendees can challenge the faculty through our interactive Q&A, and the faculty will challenge you back with a series of interactive, case scenarios.
Speakers:
Sikander Ailawadhi , MD
Mayo Clinic
Jacksonville, FLAjai Chari , MD
Division of Hematology/Oncology, Mount Sinai School of Medicine
New York, NYCaitlan Bose , Answers in CME
Registration for In-Person Program
Email: [email protected]Controlling and Conquering CLL: Guidance on Modern Targeted Options, Innovative Combinations, and Sequential Management
This program is supported by AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
This CME/MOC activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and CLL Society.
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20CDThis activity is supported by independent educational grants from AbbVie; AstraZeneca; Lilly; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Choosing well and wisely when deciding on the management of CLL has never been more important. Modern therapeutic platforms based on BTKi and BCL2i have demonstrated efficacy against higher-risk disease, in the relapsed/refractory setting, and as combination or sequential strategies, and newer chemosparing combinations and non-covalent BTKi are poised to overcome challenges in CLL. How will these developments be used going forward, and is long-lasting disease suppression an achievable goal?
Find out by joining an expert panel convened to take on the challenges of CLL and who will share real-world cases to provide guidance on how to implement modern treatment protocols and cover topics such as: choosing between continuous or fixed-duration first-line regimens; BTKi/BCL2i combination platforms; and sequential therapy with non-covalent BTKi options. In partnership with the CLL Society, these important topics will be framed by patient perspectives, including commentary from CLL survivors.
Chair:
Prof. John G. Gribben , MD, DSc
Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
London, United KingdomSpeakers:
John N. Allan , MD
Weill Cornell Medicine
New York, NYNicole Lamanna , MD
Herbert Irving Comprehensive Cancer Center, New York-Presbyterian/Columbia University Medical Center
New York, NYMeghan C. Thompson , MD
Memorial Sloan Kettering Cancer Center
New York, NYLeigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramExperts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
This program is supported by Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc.; Curis, Inc.
The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 5 clinical experts to highlight novel agents in the management of AML, including the latest clinical data and application of targeted therapies, combination, maintenance therapy, and beyond.
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6AChair:
Naval Daver , MD
The University of Texas MD Anderson Cancer Center
Houston, TXSpeakers:
Courtney D. DiNardo , MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, TXGail J. Roboz , MD
Weill Cornell Medicine and The New York Presbyterian Hospital
New York, NYEytan M. Stein , MD
Memorial Sloan Kettering Cancer Center
New York, NYKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramHitting the Mark? Targeted Antibody-Based Therapy for Diffuse Large B-cell Lymphoma
This program is supported by Genmab, US Inc. and ADC Therapeutics
Join expert DLBCL faculty as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of antibody-based therapies into treatment plans for DLBCL. Informed by real-world data from a recent quality improvement initiative, this satellite symposium will support DLBCL care teams in examining the latest evidence, differentiating new and emerging antibody-based therapies for DLBCL, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, a whiteboard animation video will be featured during the presentation, designed to illustrate the unique mechanisms of action of new and emerging novel, targeted antibody-based therapies for DLBCL. Altogether, this satellite symposium will harness real-world experiences providing DLBCL care to deepen the impact of the education on new and emerging antibody-based therapy, utilizing a case-based approach to provide a basis for discussion and strategy to enhance patient-centered care.
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6DEChair:
Krish Patel , MD
Swedish Cancer Institute
Seattle, WASpeakers:
Douglas Burgoyne , PharmD, FAMCP
University of Utah
Salt Lake City, UTKrish Patel , MD
Swedish Cancer Institute
Seattle, WAPeter A. Riedell , MD
University of Chicago
Chicago, ILJill Friedman , PRIME Education, LLC
Email: [email protected]Medical Crossfire: how Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
This program is supported by American Regent, Inc.
There is an the unmet need for educational activities designed to close the gap in knowledge for physicians who treat or manage patients with cancer-related anemia. This program is centered around improving medical practices and patient care for those who are diagnosed with cancer-related iron deficiency anemia and will feature a mix of didactic and discussion sessions. This satellite will aim to provide an overview of pathophysiologic mechanisms and prevalence of cancer-related iron deficiency anemia, current applications of iron supplementation including a breakdown of oral versus IV iron, case discussions, and what oncologists/hematologists can do to address challenges with diagnosis and management of patients.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 24-26Chair:
George M. Rodgers , MD, PhD
Univ. of Utah Medical Center
Salt Lake City, UTSpeaker:
Patricia A. Locantore-Ford , MD
Pennsylvania Hospital
Philadelphia, PAJim Palatine , Physicians Education Resource
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramMedical Crossfire®:Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL
This program is supported by Amgen, Inc., Takeda Oncology
This Medical Crossfire® will provide an ideal format for the ALL care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 11-13Chair:
Elias Jabbour , MD
University of Texas M.D. Anderson Cancer Ctr.
Houston, TXSpeakers:
Lia Gore , MD
University of Colorado Cancer Center
Aurora, COHagop M. Kantarjian , MD
University of Texas MD Anderson Cancer Center
Houston, TXAaron C. Logan , MD, PhD
University of California San Francisco
San Francisco, CAClaire Roddie , MD, PhD
University College London
LONDON, GBRKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramMore Than a Disease: Exploring the Patient Journey for Chronic Immune Thrombocytopenia
This program is supported by an independent educational grant from Argenx US, Inc., Sanofi, and Novartis Oncology.
This 90-minute, live, interactive symposium will feature expert faculty as well as a patient with ITP to underscore the value of the patient voice throughout the management of ITP. Expert faculty will provide a detailed overview of the mechanisms of ITP and its key clinical features, present diagnostic and treatment challenges and how to overcome them, as well as discuss data on current and emerging therapies to inform the best clinical choices for patients. A big emphasis will be placed on the importance of shared-decision making with the interdisciplinary team for improving outcomes for their patients. Interactive polling questions and a Q&A session will allow for audience engagement and added learning.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 2-4Chair:
Spero Cataland , MD
Ohio State University Comprehensive Cancer Center
Columbus, OHSpeakers:
Srikanth Nagalla , MBBS
Miami Cancer Institute
Miami, FLMarie Scully , MD
University College London
London, ENG, United KingdomHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramMultiple Myeloma: Clinical Challenges for the Community Clinician
This program is supported by Bristol Myers Squibb, Janssen, Sanofi, Karyopharm, and Legend
This 90-minute interactive symposium will feature a panel of experts evaluating the intricacies of care for patients with multiple myeloma through a series of challenging clinical cases. They will provide expert guidance and real-world perspectives related to optimizing outcomes at each phase of the treatment journey. Attendees can participate in interactive case challenges and engage directly with the expert panel in a closing Q&A session.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 5-6Chair:
C. Ola Landgren , MD, PhD
Sylvester Comprehensive Cancer Center, University of Miami
Miami, FLSpeakers:
Luciano Costa , MD,PhD
The University of Alabama at Birmingham
Vestavia, ALNisha S. Joseph , MD
Winship Cancer Institute of Emory University
Atlanta,Harmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramOptimizing Myelofibrosis Management With Current and Emerging Therapies
This program is supported by AbbVie, Bristol -Myers Squibb Company, GSK, and Karyopharm Therapeutics
This 90-minute symposium will present a comprehensive review of the recent updates related to current and emerging therapies in MF. Featuring a lively and engaging format resembling a talk show, 3 expert faculty in MF will discuss the evolving MF treatment paradigm. Discussion will review the current treatment landscape, emerging therapies, and practical management strategies to optimize patient outcomes. The program will also contain a “Query the Experts”-style Q&A, in which each panelist takes turns presenting a challenging case scenario to the others to elicit discussion and compare approaches, with accompanying audience polling questions to stimulate discussion.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 8-9Chair:
Prithviraj Bose , MD
MD Anderson Cancer Center
Houston, TXSpeakers:
Stephen T. Oh , MD,PhD
Washington University School of Medicine
Saint Louis, MONikolai A. Podoltsev , MD, PhD
Yale School of Medicine
New Haven, CTHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramReimagining Outcomes in Hemophilia: Improving Efficacy and Reducing Treatment Burden with High-Sustained Factor and Non-Factor Replacement Therapies
This program is supported by Sanofi
This session will explore the latest understanding of hemostasis as it relates to the pathology of hemophilia, highlight the mechanism of action, using clinical animations, of new and emerging hemophilia treatments, discuss the efficacy and safety of novel therapies, and utilize clinical case scenarios to explore practical implications of newly approved and upcoming therapies.
11:00 a.m. - 2:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 18-19Chair:
Guy Young , MD
Children's Hospital Los Angeles
Los Angeles, CASpeakers:
Glaivy Batsuli , MD
Stanford University
Stanford, CACindy A. Leissinger , MD
Tulane University School of Medicine
New Orleans, LACathy Zehr , Catalyst Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramShow Me the Data™: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?
This program is supported by Geron Corporation, Incyte Corporation, Protagonist Therapeutics, PharmaEssentia USA
The live portion of this curriculum will be presented as a 2.5-hour Friday Satellite Symposium (FSS) held prior to the 2023 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with myeloproliferative neoplasms (MPNs) with novel treatment approaches and emerging treatment strategies in the context of current paradigms.
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Room 6BAfter each “decision point,” the chair will challenge the faculty member to Show Me the Data! that backs up their decision-making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision-making. ARS will be utilized throughout to identify learners current knowledge and competence levels at the beginning and conclusion of each case scenario.
To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.
Chair:
Andrew T. Kuykendall , MD
Moffitt Cancer Center
Tampa, FLSpeakers:
Gabriela S. Hobbs , MD
Massachusetts General Hospital
Boston, MABarbara Mora , MD
Division of Hematology, Ospedale ASST Sette Laghi, University of Insubria
Varese, ItalyNaveen Pemmaraju , MD
MD Anderson Cancer Cneter
Houston, TXKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramUntangling Amyloidosis 2023: Diagnosis, Prognosis, Selection of Individualized Therapy, and Management of Difficult Clinical Complications
This program is supported by Prothena, Amyloidosis Foundation Amyloidosis Support Group
The Karmanos Cancer Institute, in collaboration with the Amyloidosis Support Groups, Inc., is developing a CME symposium to be conducted on Friday, December 8th, 2023, preceding the annual American Society of Hematology (ASH) meeting. It will consist of evidence-based presentations focused on the diagnosis, pathophysiology, prognosis, and treatment of systemic amyloidosis. The complexities of making a timely, accurate diagnosis of amyloidosis will be discussed, with emphasis placed on distinguishing AL amyloidosis from the other most common type of amyloidosis, ATTR. Selection of appropriate initial anti-plasma cell therapy of AL amyloidosis will be highlighted. Investigational light chain and fibril-directed agents will be discussed, as will novel potential therapeutic strategies mirroring approved ATTR therapies. Finally, we will review the pathophysiology of bleeding and clotting complications in AL amyloidosis, providing attendees practical clinical management guidance. We intend to live-stream the presentations to expand the audience beyond those attending in-person. The program is intended to be interactive and the live audience will be asked to provide opinions and answers to questions intermittently throughout the program via an audience response system (ARS). A panel discussion after the speakers' presentations will provide an opportunity to address questions from the live audience.
11:00 a.m. - 2:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20ABChair:
Jeffrey A. Zonder
Karmanos Cancer Institute
Detroit, MISpeakers:
Giada Bianchi , MD
Brigham and Women's Hospital
Boston, MASimon Gibbs , FRACP, FRCPA, MBBS
Eastern Health
Box Hill, AustraliaEli Muchtar , MD
Mayo Clinic
Rochester, MNLaura Obici , MD
Fondazione IRCCS Policlinico San Matteo
Pavia, ITAChristiane A. Houde , Karmanos Cancer Institute
Registration for In-Person Program
Email: [email protected]
Registration for Virtual Program3
Late Afternoon Symposia
3:00 p.m. - 6:00 p.m.
Pacific timeA Rare Day in the Community Hematology Clinic: Interesting Cases in Classical Hematology
This program is supported by Agios, Novartis Oncology
Sickle cell disease (SCD) is the world’s most common genetic disease, affecting more than 3 million people worldwide. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired form of intravascular hemolysis with a worldwide incidence of five to six cases per million people and a prevalence of 16 cases per million people. In this live symposium, 2 experts in the field of SCD and PNH will delve into the identification, diagnosis, treatment nuances, and overall management of these 2 classic hematologic malignancies using case studies as a practical guide. Additionally, our panel will discuss the implications of health inequities and how to address more accessible, equitable, cost-effective, and person-centered care for patients affected with PNH and SCD.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 11-13Chair:
Morag Griffin , FRCPath,MRCP
St James's University Hospital
Leeds, United KingdomSpeaker:
Michael R. DeBaun , MD, MPH
Vanderbilt University Medical Center
Nashville, TNHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramAchieving “Next-Level” Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine
This program is supported by AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.
This CME activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 15-17This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.
The modern management of acute myeloid leukemia (AML) has changed dramatically in recent years as innovative therapeutics, including FLT3, IDH, and BCL2 inhibitors; novel radioimmunoconjugate approaches; and newer epigenetic and targeted therapeutics (eg, menin inhibitors), have overturned the largely cytarabine-based chemotherapy standard of patient care. Strategic treatment planning is now more important than ever to ensure the safe delivery of different therapeutic drug classes.
To explore this “next level” of AML management, PeerView’s experts will use case-based Clinical Consult debates to illustrate how varying baseline patient features can alter treatment decisions and discuss strategies to leverage the fruits of new science to improve patient care. Each discussion will be supported by mini lectures covering current science and modern clinical decision-making strategies in a diversity of AML settings and patient presentations. Join us to achieve “next-level” care for your patients with AML!
Chair:
Sergio A. Giralt , MD, FACP
Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center
New York, NYSpeakers:
Pinkal Desai , MD, MPH
Weill Cornell Medicine, The New York Presbyterian Hospital
New York, NYGhayas C. Issa , MD
The University of Texas MD Anderson Cancer Center
Houston, TXTapan M. Kadia , MD
The University of Texas MD Anderson Cancer Center
Houston, TXSelina M Luger , MD,FRCPC
Perelman School of Medicine, Hospital of the University of Pennsylvania
Philadelphia, PALeigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramAdvances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease
This program is supported by Sanofi. Provided by Clinical Care Options, LLC.
This interactive symposium will feature a unique learning opportunity to gain and update on the latest clinical advances in the care of patients with cold agglutinin disease (CAD). The symposium format will include presentations and case-based panel discussions with perspectives and treatment recommendations from multiple experts. In addition, the panel will address audience questions and practice challenges identified in the “Live Case and Question Submission”, which can be sent directly to the symposium faculty. You can expect to receive a review of cutting-edge clinical evidence along with a presentation of evolving treatment algorithms for CAD into 2024. Program topics will include an overview CAD and the associated pathophysiology, clinical presentation and diagnosis of CAD; current/evolving management algorithm for the patient with newly diagnosed CAD and the management of CAD-related anemia, fatigue, and hemoglobinuria; challenges and strategies to address quality of life in patients with CAD; plus novel treatments on the horizon and future directions.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
San Diego Ballroom ABChair:
Catherine Broome , MD
Georgetown University
Washington, DCSpeakers:
David Dingli , MD
Mayo Clinic
Rochester, MNDeva Sharma , MD
Vanderbilt University School of Medicine
Nashville, TNIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramAdvances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care
This program is supported by an educational grant from Genmab US, Inc. and AbbVie
This activity is intended to educate clinicians regarding the use and integration of new and emerging BCMA-targeted therapies in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). In the “Care Team Forum,” an expert panel will present 3 series of didactic slides, followed by discussion that will include a patient with R/R DLBCL; they will share key aspects of their therapeutic journey. Polling questions will be interspersed throughout the symposium to assess improvements in knowledge and competence among attendees.
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 30 A-EChair:
Joshua Brody , MD
Icahn School of Medicine at Mount Sinai
New York, NYSpeakers:
Lorenzo Falchi , MD
Memorial Sloan Kettering Cancer Center
New York, NYCatherine Thieblemont , MD, PhD
Université de Paris
Paris, FranceErika Sinofsky , RMEI Medical Education, LLC
Email: [email protected]Advancing cTTP Care Through Integration of the Latest Clinical Evidence
This program is supported by This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. This activity is provided by PRIME Education. There is no fee to participate.
Join expert cTTP faculty as they take a deep dive into the latest clinical evidence and practical considerations for evidence-based integration of emerging treatment and management strategies for cTTP. Informed by real-world data from a recent hematology provider survey to uncover key gaps and barriers faced in the treatment and management of cTTP, this satellite symposium will support hematology care teams in examining and integrating the latest evidence on cTTP treatment and management into clinical practice. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, a whiteboard animation video will be featured during the presentation, designed to illustrate the pathophysiology of cTTP and novel mechanisms of action of emerging cTTP treatments. Altogether, this satellite symposium will harness real-world experiences providing cTTP care to deepen the impact of the education on emerging evidence, utilizing a case-based approach to provide a basis for discussion and strategy to enhance patient-centered care.
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20ABSpeaker:
Thomas L. Ortel , MD, PhD
Duke University Medical Center
Durham, NCEryn Litvinas , PRIME Education, LLC
Email: [email protected]AL Amyloidosis: Advancements and Future Trends on Diagnosis and Individualized Treatment Approaches
This program is supported by Educational grants from Alexion Pharmaceuticals; Janssen Biotech Inc., administered by Janssen Scientific Affairs, LLC; and Prothena. Provided by Clinical Care Options, LLC.
This interactive symposium will feature presentations and case-based panel discussions with perspectives and treatment recommendations from experts. Participate in our unique "Live Case and Question Submission", forwarding your queries and real-life cases to our faculty for tailor-made insights. Experts will explore the current state of AL amyloidosis treatment, dissect breakthrough clinical evidence, and anticipate evolving strategies into 2024. Key topics include a deep dive into the biology, clinical presentation, and diagnostic approach for AL amyloidosis, a review of the latest treatment guidelines, insights into managing newly diagnosed and relapsed AL amyloidosis, future directions in treatment, and supportive management strategies for improving patients' quality of life. Enrich your understanding, challenge your clinical skills, and contribute to our insightful dialogue on AL amyloidosis in this dynamic, interactive symposium.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 21-22Chair:
Angela Dispenzieri , MD
Mayo Clinic
Rochester, MNSpeaker:
Ashutosh D. Wechalekar , MBBS,DM,FRCP,FRCPath
University College London Hospitals
London, United KingdomIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramAmplifying New and Emerging Clinical Evidence in the Treatment and Management of Myelodysplastic Syndrome
This program is supported by Gilead Sciences, Inc.
Join expert MDS faculty as they take a deep dive into the latest clinical evidence and applications for MDS treatment and management. Informed by provider surveys designed to assess knowledge and confidence gaps in MDS testing, risk assessment, and differentiating new and emerging therapies, as well as barriers to integrating the latest evidence into clinical practice, this satellite symposium will support MDS care teams in examining the latest evidence, differentiating new and emerging therapies for MDS, and addressing barriers to novel therapy adoption. The topics for discussion by the expert faculty panel will be supported by clinical cases and enhanced by interactive polling questions and live questions submitted by attendees throughout the presentation. Additionally, through partnership with the MDS Foundation, a patient vignette will be incorporated into the symposium highlighting disease burden and real-world experiences in care to deepen the impact of the education and provide a basis for discussion and strategy to enhance patient-centered care.
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6DEChair:
Amer M. Zeidan , MBBS, MHS
Yale University
New Haven, CTSpeakers:
Douglas Burgoyne , PharmD, FAMCP
University of Utah
Salt Lake City, UTRami S. Komrokji , MD
Moffitt Cancer Center
Tampa, FLEryn Litvinas , PRIME Education, LLC
Email: [email protected]An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma
This program is supported by Educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Provided by Clinical Care Options, LLC.
This dynamic symposium will combine engaging presentations and case-oriented panel discussions, showcasing expert opinions and treatment advice for relapsed/refractory (R/R) Follicular Lymphoma (FL). Directly engage with the expert panelists during the "Live Case and Question Submission" sessions during which you can present your questions and real-world cases to our experienced faculty for customized guidance. The symposium will navigate the current landscape of R/R FL treatment, unpack ground-breaking clinical research, and project future strategies into 2024. This experience promises to enrich your understanding of R/R FL, challenge your clinical acumen, and empower you to implement the latest knowledge in your practice. We invite you to contribute to this thought-provoking dialogue on R/R FL, shaping the discourse and contributing to the collective understanding of this critical area.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 18-19Chair:
Julie M. Vose , MD, MBA
Univeristy of Nebraska Medical Center
Omaha, NESpeakers:
Peter Martin , MD
Weill Cornell Medical College
New York, NYSonali M. Smith
University of Chicago
Chicago, ILIshana Fleurant , Clinical Care Options, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramBEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Chronic Lymphocytic Leukemia (Part 3 of a 4-part CME-accredited Symposia Series)
This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb and Lilly
This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of chronic lymphocytic leukemia (CLL). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.
3:00 p.m. - 6:00 p.m. Pacific time
Omni San Diego
Grand Ballroom, 4At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.
Chair:
Neil Love , MD
Research To Practice
Key Biscayne, FLSpeakers:
Farrukh T. Awan , MD
The University of Texas
Dallas, TXMatthew S Davids , MD, MMSc
Dana-Farber Cancer Institute
Boston, MAStephen J. Schuster , MD
University of Pennsylvania
Philadelphia, PAWilliam G. Wierda , MD, PhD
MD Anderson Cancer Center
Houston, TXJennifer A. Woyach , MD
The Ohio State University Comprehensive Cancer Center
Columbus, OHSylvia Eriksen , Research To Practice
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramCase Challenges in Myelofibrosis for the Community Clinician
This program is supported by CTI Biopharma Corp
Three experts will engage in a case-based discussion of clinical data, real-world experience, and optimal management strategies for the treatment of higher-risk MF. Patient cases will be introduced and revisited throughout the program to illustrate how experts interpret and apply the latest clinical data to various case scenarios. Discussion will center around the importance of ongoing prognostic risk stratification and symptom assessment; considerations in treatment selection and sequencing, including optimizing dosage, assessing treatment resistance or intolerance, and determining when and how to switch therapies; prevention and mitigation of adverse events; and the role of allogeneic transplant and clinical trials. Learners will be prompted to share their thoughts throughout the program in audience polls and the faculty will conclude with an interactive Q&A session.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 5-6Chair:
Ruben A. Mesa , MD
Atrium Health Levine Cancer Institute
Charlotte, NCSpeakers:
Angela G. Fleischman , MD,PhD
University of California, Irvine
Irvine, CARaajit K. Rampal , MD, PhD
Memorial Sloan Kettering Cancer Institute
New York, NYHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramChanging the Path of Myelofibrosis: Exploring How We Can Do More for Our Patients
This program is supported by Morphosys
Myelofibrosis (MF) is a rare disease that has a significant impact on patient’s quality of life. While many remain symptom-free for years, ultimately symptoms impose a major burden. While Janus kinase (JAK) inhibitors play an important role in treating MF, a variety of novel targeted therapies are in clinical development that have the potential to prevent/delay resistance to ruxolitinib, change the course of the disease, and advance patient outcomes. This interactive symposium will start by providing an overview of the challenges associated with current management from a physician’s perspective followed by an interview with a patient with MF to highlight the challenges that they face. We then continue with a deeper dive into the biological and genetic path of MF, as well as the path of epigenetic dysregulation fueling the development of epigenetic therapies. The session will end with a group discussion reviewing how these new developments may positively impact the evolving journey of patients with MF.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 8-9Chair:
John Mascarenhas , MD
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
New York, NYSpeakers:
Claire N Harrison
Guy’s and St. Thomas’ NHS Foundation Trust
London, ENG, United KingdomRonald Hoffman , MD
Tisch Cancer Institute
New York, NYAnn Mullally , MD
Dana-Farber Cancer Institute
Boston, MAHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramComplement Wheel: Optimizing Care for Patients with aHUS, HSCT-TMA, and PNH
This program is supported by Alexion Pharmaceuticals, Inc
In this live, interactive program, expert faculty will present and discuss the most recent and relevant data and clinical advances as well as provide their expert perspectives around three rare, complex hematologic disorders marked by dysfunction of the complement cascade: atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). The patient experience using vignettes will be highlighted throughout the event with an emphasis on optimizing clinical decision-making.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 2-4Chair:
Ilene C. Weitz , MD
Keck-USC School of Medicine
Los Angeles, CASpeakers:
Vincent T. Ho , MD
Harvard Medical School
Boston, MADavid J Kuter , MD,DPhil
Massachusetts General Hospital
Boston, MAHarmony Washington , Medscape Oncology
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramComprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans
This program is supported by Vertex Pharmaceuticals
This educational activity will explore disease management approaches in SCD by focusing on
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6B
important components of successful pain management, the challenges of complications and
comorbid conditions in patients with SCD, the changing needs of patients across the lifespan
including issues pertaining to reproductive and sexual health, and the evolving treatment
landscape for patients with SCD.Chair:
Biree Andemariam , MD
University of Connecticut Health
Farmington, CTSpeakers:
Lydia H Pecker , MD
Johns Hopkins University School of Medicine
Baltimore, MDNirmish Shah , MD
Duke University Medical Center
Cary, NCJames Palatine , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramPutting Your Stamp on the Next Generation of Care in CML – Improving Outcomes from Frontline to R/R Treatment Settings
This program is supported by Novartis Pharmaceuticals Corporation
The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together clinical experts to highlight novel agents in the management of frontline and R/R CML, including the latest clinical data and application of novel TKIs and next-generation treatment approaches, including best practices for monitoring and managing adverse events with a multidisciplinary team in the United States and around the world! Considerations for advanced practice professionals, pharmacists and community clinicians will also be addressed throughout the educational event. Based on positive feedback from attendees at the 2022 ASH Friday Satellite Symposia, each presentation will follow with question-and-answer discussion from the floor.
3:00 p.m. - 6:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 24-26Chair:
Jorge Cortes , MD
Augusta University
Augusta, GASpeakers:
Andreas Hochhaus , MD
Universitätsklinikum Jena
Jena, GermanyAmanda Rodriguez , PA-C
Moffitt Cancer Center
Tampa, FLKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramReal-World Applications of Asparaginase Formulations in ALL and LBL from Pediatric/AYA to Adult Treatment: Maximizing Clinical Benefits Through Multidisciplinary Care
This program is supported by PER Oncology
The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 4 clinical experts to highlight novel agents in the management of ALL/LBL, including the latest clinical data and application of asparaginase formulations across the ALL continuum, including best practices for monitoring and managing hypersensitivity and silent inactivation reactions in the United States and around the world! Considerations for advanced practice professionals and community clinicians will also be addressed throughout the educational event.
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Room 6AChair:
Rachel E. Rau , MD
Texas Children's Hospital/Baylor College of Medicine
Houston, TXSpeakers:
Luke Maese , DO
Huntsman Cancer Institute, University of Utah
Salt Lake City, UTEtan Orgel , MD
Keck School of Medicine of University of Southern California
Los Angeles, CAKelly Donald , Physicians' Education Resource, LLC
Registration for In-Person Program
Email: [email protected]
Registration for Virtual ProgramToward a Brighter Future for Preventing COVID-19 in Patients With Hematologic Malignancies: Leveraging the Power of Current Strategies and Next-Generation Agents
This program is supported by AstraZeneca LP
This CME activity is provided by Penn State College of Medicine and developed with our educational partner, PVI, PeerView Institute for Medical Education.
3:00 p.m. - 6:00 p.m. Pacific time
San Diego Convention Center
Ballroom 20CDThis activity is supported by an independent educational grant from AstraZeneca LP.
Hundreds of thousands of patients with hematologic malignancies in the United States must take medications that leave them immunocompromised. Though vaccinated, these patients have hundred-fold higher rates of serious breakthrough COVID-19 infections compared with healthy individuals because of inadequate responses to vaccination. Tixagevimab/cilgavimab lost its emergency use authorization as prevention for immunocompromised patients because of its lack of efficacy against newer variants. However, next-generation prevention agents are in development, including a new monoclonal antibody, AZD3152. Meanwhile prevention of COVID-19 for immunocompromised people is shifting to a more individualized approach, increasing the complexity of clinical decision-making.
PeerView's expert faculty will discuss strategies to engage patients with elevated risk of serious COVID-19 infection in the development of customized prevention plans. In addition, they will explore approaches to overcoming real-time barriers to access and use of available options for prevention of serious COVID-19 illness.
Chair:
Shmuel Shoham , MD
Johns Hopkins University School of Medicine
Baltimore, MDSpeakers:
Ghady Haidar , MD
University of Pittsburgh and UPMC
Pittsburgh, PACarol Ann Huff , MD
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MDLeigh Anne Bongiovanni , PVI, PeerView Institute for Medical Education
Registration for In-Person Program
Email: [email protected]
Registration for Virtual Program4
Evening Symposia
7:00 p.m. - 10:00 p.m.
Pacific timeBEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)
This program is supported by educational grants from Abbvie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi
This CME-accredited program, offered for in-person and virtual attendees, will focus on the management of multiple myeloma (MM). Five investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 clinical investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty” clinical investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this survey and share the scientific rationale guiding their thinking.
7:00 p.m. - 10:00 p.m. Pacific time
Omni San Diego
Grand Ballroom, 4At the live event, for each module, Dr Love will present results from the case-based survey, followed by video excerpts from the non-faculty member interviews. The faculty panel will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty member will also deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have to complete the same survey and present their own questions for discussion.
Chair:
Neil Love , MD
Research To Practice
Key Biscayne, FLSpeakers:
Amrita Krishnan , MD
City of Hope
Irvine, CASagar Lonial , MD
Winship Cancer Institute, School of Medicine, Emory University
Atlanta, GARobert Z. Orlowski , MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, TXNoopur Raje , MD
Massachusetts General Hospital Cancer Center
Boston, MAPaul G. Richardson , MD
Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School
Boston, MASylvia Eriksen , Research To Practice
Email: [email protected]Evolving Paradigms: Novel Approaches and Best Practices for Hodgkin Lymphoma
This program is supported by Bristol Myers Squibb and Seagen
This 90-minute symposium will feature 3 experts in treating HL and is designed to highlight recent clinical trial data in cHL, real-world outcomes, and provide patient case examples on how to translate these data into clinical practice. Panel discussion and audience polling questions will be interwoven throughout the program to enhance dialogue.
7:00 p.m. - 10:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Marriott Grand Ballroom 11-13Harmony Washington , Medscape Oncology
Email: [email protected]How Do We Treat GvHD Today... And Tomorrow? Treatment Algorithms for Key Decision Points in Prophylaxis Care, Acute, and Chronic Disease
This program is supported by Incyte Corporation; ST Shared Services LLC, a Mallinckrodt company; Equillium Bio
The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 4 clinical experts to highlight novel agents in the management of acute and chronic GvHD, as well as prophylaxis care. Novel and investigational approaches will be considered across key decision points in care, with ample discussion from the expert panel and from “the floor” on how we treat GvHD today... and tomorrow!
7:00 p.m. - 10:00 p.m. Pacific time
Marriott Marquis San Diego Marina
Pacific Ballroom Salons 24-26Chair:
Corey Cutler
Dana-Farber Cancer Institute
Boston, MASpeakers:
Hannah Choe , MD
The Ohio State University Wexner Medical Center
Columbus, OHCarrie L. Kitko
Vanderbilt University
Nashville, TNMiguel-Angel Perales , MD
Memorial Sloan Kettering Cancer Center
New York, NYKelly Donald , Physicians' Education Resource, LLC
Email: [email protected]